Royal Bank Of Canada Neu Base Therapeutics, Inc. Transaction History

Royal Bank Of Canada

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.18 - $0.3 $98 - $163	-546 Reduced 94.79%	30 $0
Q3 2022 Nov 14, 2022	SELL	$0.41 - $1.3 $19,647 - $62,297	-47,921 Reduced 98.81%	576 $0
Q2 2022 Aug 15, 2022	SELL	$0.82 - $1.93 $54,100 - $127,333	-65,976 Reduced 57.63%	48,497 $51,000
Q1 2022 May 16, 2022	BUY	$1.26 - $2.95 $56,436 - $132,133	44,791 Added 64.28%	114,473 $215,000
Q4 2021 Feb 14, 2022	BUY	$2.6 - $4.18 $96,452 - $155,065	37,097 Added 113.85%	69,682 $196,000

Q3 2021 Nov 15, 2021	SELL	$3.27 - $4.76 $174,519 - $254,041	-53,370 Reduced 62.09%	32,585 $117,000
Q2 2021 Aug 16, 2021	BUY	$4.63 - $7.34 $397,971 - $630,909	85,955 New	85,955 $412,000

Ticker NBSE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,258,700
Description
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.